Ublituximab
ATC L04AG14 · 5 markets · 7 records
AU 3 records · 3 strengths
- 150 mg/6 mLinjectionBRIUMVI
- 25 mg/mLinjectionBRIUMVI ublituximab 150 mg/6 mL concentrated injection for infusion vial
Records without a stated strength · 1 BRIUMVI
US 1 records · 1 strengths
- 150 mg/6 mLinjectionBRIUMVI
GB 1 records · 1 strengths
- 150 mg/6 mLinjectionBriumvi 150mg/6ml concentrate for solution for infusion vials
ES 1 records · 1 strengths
- 150 mginjectionBRIUMVI
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 BRIUMVI
| Strength / form / release | US | GB | AU | ES | EU |
|---|---|---|---|---|---|
| 150 mg/6 mL injection | BRIUMVI | Briumvi 150mg/6ml concentrate for solution for infusion vials | BRIUMVI | ||
| 150 mg injection | BRIUMVI | ||||
| 25 mg/mL injection | BRIUMVI ublituximab 150 mg/6 mL concentrated injection for infusion vial | ||||
unknown | BRIUMVI | BRIUMVI |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.